BioAge Labs Expands BGE-102 Program into Diabetic Macular Edema with New Clinical Trial

summarizeSummary

BioAge Labs announced the expansion of its oral NLRP3 inhibitor BGE-102 program into diabetic macular edema (DME), with plans to initiate a Phase 1b/2a clinical trial in mid-2026. This move broadens the potential applications for the drug, supported by positive preclinical and early clinical data.

check_boxKey Events

• Indication Expansion for BGE-102

  BioAge Labs announced the expansion of its oral NLRP3 inhibitor BGE-102 development program into ophthalmology, specifically targeting diabetic macular edema (DME).

• Phase 1b/2a Trial Initiation

  The company plans to initiate a Phase 1b/2a proof-of-concept clinical trial in patients with DME in mid-2026.

• Supporting Preclinical and Clinical Data

  Preclinical models showed BGE-102 preserved retinal vascular integrity in DME, and ongoing Phase 1 trials demonstrate favorable tolerability and robust reductions in inflammatory biomarkers.

• Parallel Development and Milestones

  The DME trial will run in parallel with the BGE-102 Phase 2a cardiovascular risk trial. Key milestones include Phase 1 completion and CV risk Phase 2a initiation in 1H 2026, DME trial initiation in mid-2026, and data readouts for CV risk in 2H 2026 and DME in mid-2027.

auto_awesomeAnalysis

BioAge Labs' decision to expand its BGE-102 development program into diabetic macular edema (DME) is a significant strategic move, broadening the potential market for this key asset. The initiation of a Phase 1b/2a proof-of-concept trial in mid-2026, supported by promising preclinical data and favorable tolerability in ongoing Phase 1 studies, indicates a robust pipeline progression. This expansion, alongside the existing cardiovascular risk program, demonstrates the company's ability to leverage its assets across multiple indications, potentially de-risking its development efforts and increasing the long-term value of BGE-102.